Tag Archives: Sarepta

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This is the online version of Adam’s Biotech Scorecard, a …

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Sarepta Therapeutics, the maker of a gene therapy for Duchenne …

Thomas Fuller | SOPA Images | Lightrocket | Getty Images Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatment died. U.S. regulators on Friday asked Sarepta Therapeutics to voluntarily halt shipments of its gene therapy. However, the company …

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Sarepta Therapeutics said Monday evening it will pause all shipments …

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.  Sarepta Therapeutics In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy  statnews.com Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy  Fierce Biotech Sarepta shares plunge 40% as future of its gene therapy appears at risk  CNBC Sarepta Therapeutics stock sinks …

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy  Fierce Biotech We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress  statnews.com Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug  Yahoo Finance Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths  The New York Times …

Sarepta, Verizon, Block, Tesla, Domino’s, Cleveland-Cliffs, and More Market Movers  Barron’s Stocks to Watch Monday: Verizon, Cleveland-Cliffs, Domino’s, Block  The Wall Street Journal Trending tickers: The latest investor updates on Tesla, Opendoor, Block, BP and Ryanair  Yahoo.co Biggest stock movers Monday: XYZ, SRPT, and more (XYZ:NYSE)  Seeking Alpha Biggest stock movers Monday: XYZ, and more  MSN Source link

Sarepta plans Elevidys shipments despite FDA request (SRPT)  Seeking Alpha Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys  The New York Times FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths  fda.gov We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress  statnews.com Sarepta …

WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy. The highly unusual move is a latest in a string of events that have hammered the …

Sarepta says it won’t comply with FDA request to stop shipping gene therapy Elevidys  Reuters Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys  The New York Times Sarepta shares plunge 40% as future of its gene therapy appears at risk  CNBC Third death from a Sarepta gene therapy  biocentury.com We are mothers of Duchenne patients. Recent setbacks with Sarepta must not …